Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01841996 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients
A Phase 1 study of Onychomycosis, sponsored by Meiji Seika Pharma Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT01841996 is a Phase 1 study of Onychomycosis that has completed, run by Meiji Seika Pharma Co.. The registered enrollment target is 24 participants, below the 92-participant average among 11 other Onychomycosis trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01841996, a Phase 1 study of Onychomycosis, has completed, sponsored by Meiji Seika Pharma Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study. The purpose is to determine the safety, tolerability, systemic exposure and pharmacokinetics of ME1111 after repeated daily topical application of ME1111 in a maximal use setting in adults with distal subungual onychomycosis of the toenails.
Conditions Studied
Interventions
- DRUG Vehicle Solution
- DRUG ME1111 solution
Study Locations (2)
Texas
- - Austin
- - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01841996
The ClinicalTrials.gov registry entry for NCT01841996 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 11 other Onychomycosis trials with a reported enrollment target (74% lower). The listed sponsor is Meiji Seika Pharma Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Onychomycosis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Solution is the first listed.
NCT01841996 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01841996 about?
NCT01841996 is a clinical study titled "Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients". This study is Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study. The purpose is to determine the safety, tolerability, systemic exposure and pharmacokinetics of ME1111 after repeated daily topical application of ME1111 in a maximal use setting in adults with distal subungual onychom...
What is the current status of trial NCT01841996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-03.
What conditions does trial NCT01841996 study?
This clinical trial studies the following conditions: Onychomycosis.
What interventions are being tested in trial NCT01841996?
The interventions under investigation include: Vehicle Solution (DRUG), ME1111 solution (DRUG).
Who is sponsoring clinical trial NCT01841996?
This trial is sponsored by Meiji Seika Pharma Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01841996 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Onychomycosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single-blind Evaluation of Device to Nail Micro-drilling in Onychomycosis
COMPLETED · Phase 1
-
A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
ACTIVE NOT RECRUITING · Phase 3
-
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
COMPLETED · NA
-
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
COMPLETED · Phase 2
-
Spread of Dermatophytes Among Families
COMPLETED
-
Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.